MTORX™ Platform
Epidermolytic Ichthyosis (EI)
Key Facts
About Biomendics
BioMendics is a private, pre-revenue biotech founded in 2017 and based in San Diego, CA. The company is advancing a novel platform of small molecule liquid crystal drugs, with its lead candidate in Phase II development for epidermolysis bullosa simplex (EBS). Led by founder and CEO Dr. Karen M. McGuire, BioMendics is targeting a portfolio of rare skin disorders including epidermolytic ichthyosis and pachyonychia congenita, aiming to provide the first disease-modifying treatments for these debilitating conditions.
View full company profileAbout Biomendics
BioMendics is a private, pre-revenue biotech founded in 2017 and based in San Diego, CA. The company is advancing a novel platform of small molecule liquid crystal drugs, with its lead candidate in Phase II development for epidermolysis bullosa simplex (EBS). Led by founder and CEO Dr. Karen M. McGuire, BioMendics is targeting a portfolio of rare skin disorders including epidermolytic ichthyosis and pachyonychia congenita, aiming to provide the first disease-modifying treatments for these debilitating conditions.
View full company profileAbout Biomendics
BioMendics is a private, pre-revenue biotech founded in 2017 and based in San Diego, CA. The company is advancing a novel platform of small molecule liquid crystal drugs, with its lead candidate in Phase II development for epidermolysis bullosa simplex (EBS). Led by founder and CEO Dr. Karen M. McGuire, BioMendics is targeting a portfolio of rare skin disorders including epidermolytic ichthyosis and pachyonychia congenita, aiming to provide the first disease-modifying treatments for these debilitating conditions.
View full company profile